Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Nodal staging constitutes an element of great importance in the treatment planning for early breast cancer. The ACOSOG Z0011 trial demonstrated that sentinel lymph node (SLN) biopsy alone results in rates of local control, disease-free survival, and overall survival equivalent to those seen after axillary lymph node dissection. The purpose of this study was to determine the rate of patients that fulfill the ACOSOG Z0011 inclusion criteria and to define predictive factors for non-SLN positivity.
Methods: A retrospective analysis of the breast surgery database of the Argentinian Society of Mastology was carried out. Patients were selected if they fulfilled the ACOSOG Z0011 inclusion criteria. The association of clinical and pathological factors with non-SLN positivity was evaluated in univariate and multivariate analysis.
Results: Among 8,262 patients, 973 had positive SLN, and 348 satisfied the inclusion criteria. Histological grade (G3 vs. G1-2, odds ratio (OR) 1.81; p = 0.024), tumor size (T2 vs. T1, OR 2.39; p = 0.001), and age (>50 vs. <50 years, OR 1.95; p = 0.007) were associated with non-SLN positivity in multivariate analysis.
Conclusion: Although the clinical relevance of our data is not established, older women with tumors bigger than 2 cm and/or high histological grade are at greater risk of having metastatic disease in the lymph nodes if axillary lymph node dissection is avoided. This subgroup of patients represents only 30% of the trial population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381814 | PMC |
| http://dx.doi.org/10.1159/000488277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management and Outcomes in Patients with Breast Cancer with 1-of-1 and 2-of-2 Positive Sentinel Nodes.
Ann Surg Oncol
August 2025
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Background: The ACOSOG-Z0011 and AMAROS trials showed that axillary lymph node dissection (ALND) provided no benefit for patients with 1-2 positive sentinel lymph nodes (+SLNs). There remains apprehension to omit ALND for patients in whom only 1-2 SLNs are retrieved and all are positive. This study evaluates current practices and pathological findings when ALND is pursued.
View Article and Find Full Text PDFPreoperative Axillary Ultrasound in the Era of Z0011: A Model for Predicting High Axillary Disease Burden.
Curr Oncol
May 2025
Department of Surgery, University of Alberta, Edmonton, AB T6G 2B7, Canada.
The ACOSOG Z0011 and IBCSG 23-01 trials demonstrated that axillary lymph node dissection (ALND) offers no prognostic benefit in breast cancer patients with clinically negative axillae and low disease burden (one to two positive nodes) on sentinel lymph node biopsy (SLNB). However, uncertainty remains regarding the management of patients with clinically negative axillae (cN0) who are found to have suspicious lymph nodes on imaging that are subsequently confirmed positive by biopsy. The current practice often directs these patients to upfront ALND, potentially exposing them to unnecessary surgical morbidity.
View Article and Find Full Text PDFChanging practice patterns in axillary management for patients with node-positive breast cancer towards increased use of sentinel lymph node biopsy-alone after neoadjuvant chemotherapy: results of a survey (MF17-01) among Turkish surgeons.
Langenbecks Arch Surg
June 2025
Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Türkiye.
Background: This study aimed to determine the knowledge of major benchmark trials among Turkish general surgeons to investigate if they have adopted the results in their practice.
Methods: A total of 101 general surgeons from the Turkish Federation of Breast Diseases Society (TFBDS) were asked to complete a survey that included 24 multiple-choice questions regarding the surgical practice in axillary surgery for early and locally advanced breast cancer.
Results: Most surgeons were familiar with prospective axillary surgery studies including ACOSOG Z0011 (n = 77, 76.
Trends in the rate of axillary clearance following the publication of the ACOSOG Z0011 trial: A systematic review.
Eur J Surg Oncol
August 2025
University of Sheffield Medical School, Beech Hill Rd, Broomhall, Sheffield, S10 2RX, UK; School of Medicine and Population Health, University of Sheffield, Barber House, 387 Glossop Road, Sheffield, S10 2HQ, UK.
Axillary surgery for breast cancer has seen significant de-escalation in the past three decades. The ACOSOG Z0011 trial suggested that completion axillary clearance was not necessary in women with low disease burden after sentinel node biopsy (SLNB). Flaws in the design of the trial undermined confidence in its findings which delayed widespread adoption and caused practice heterogeneity globally.
View Article and Find Full Text PDFHow can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
Breast Cancer Res Treat
July 2025
Departement of Surgical Oncology, Georges-François Leclerc Cancer Center, 1 rue du Professeur Marion, 21000, Dijon, France.
Purpose: Results of MonarchE trial have changed adjuvant therapy for estrogen-receptor-positive (ER+), HER-2-negative breast cancer. Given the importance of the extent of nodal disease in this study, surgical management of the axilla has resurfaced as a question asked at multidisciplinary boards.
Methods: Using data from a cohort of Werkoff (JCO, 2009) in which patients underwent both sentinel lymph node(SLN) biopsy and axillary node dissection (ALND), we assessed the proportion of patients in whom the absence of ALND would have led to a lack of awareness of "high-risk" status.